Completed PHASE3 NCT00073827

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

Sponsor: Sumitomo Pharma America, Inc.

Conditions Asthma

Interventions Placebo levalbuterol tartrate MDI racemic albuterol MDI

Updated 8 times since 2017 Last updated: Feb 21, 2012 Started: May 31, 2002 Primary completion: Jan 31, 2003 Completion: Jan 31, 2003

This PHASE3 trial investigates Asthma and is currently completed. Sumitomo Pharma America, Inc. leads this study, which shows 8 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2023 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2023 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sumitomo Pharma America, Inc.

Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Amarillo, United States , Asheville, United States , Baltimore, United States , Charleston, United States , Chester, United States , Cincinnati, United States , Columbia, United States , Corona, United States , Dallas, United States and 48 more locations